Dr Gupta on Considerations for Frontline Treatment Selection in HR+/HER2-Negative Breast Cancer

Dr Gupta on Considerations for Frontline Treatment Selection in HR+/HER2-Negative Breast Cancer

Tanya Gupta, MD, shares factors informing frontline treatment approaches for metastatic hormone receptor–positive, HER2-negative breast cancer.

All About Breast Cancer Hormone Receptor Status | Breast Cancer Research Foundation

Learn what breast cancer hormone receptors are and why they’re important in diagnosis and treatmentThanks to research, there are many FDA-approved treatments for breast cancer. But how do doctors determine the best therapies for each patient? Part of that process relies on identifying your breast cancer hormone receptor status. Knowledge is power. Stay empowered with the latest news, insights, and resources delivered to your inbox. …

Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.